Understanding micrometastatic disease and anoikis resistance in ewing family of tumors and osteosarcoma

Oncologist

Volumn 15, Issue 6, 2010, Pages 627-635

  Strauss, Sandra J ^a   Ng, Tony ^b   Mendoza Naranjo, Ariadna ^a   Whelan, Jeremy ^a   Sorensen, Poul H B ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Anoikis; Ewing family of tumors; EWS FLI1; Micrometastatic disease; Osteosarcoma

Indexed keywords

ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA4 INTEGRIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CAVEOLIN 1; CYCLIN D1; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EZRIN; FOCAL ADHESION KINASE; INTEGRIN LINKED KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN TYROSINE KINASE A; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR BLOCKING AGENT; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; Y BOX BINDING PROTEIN 1;

ANOIKIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL MIGRATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG TARGETING; EWING SARCOMA; EXTRACELLULAR MATRIX; HUMAN; MICROMETASTASIS; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BONE TUMOR; METASTASIS; PATHOLOGY; PHYSIOLOGY; SECONDARY;

ANOIKIS; BONE NEOPLASMS; HUMANS; NEOPLASM METASTASIS; OSTEOSARCOMA; SARCOMA, EWING;

EID: 77954987492     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0093     Document Type: Article

References (89)

1. Sporn MB. The war on cancer. Lancet 1996;347:1377-1381.
2. Riethdorf S, Wikman H, Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008;123:1991-2006.
3. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
4. Braun S, Kentenich C, Janni W et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000;18:80-86.
5. Janni W, Gastroph S, Hepp F et al. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer 2000;88:2252-2259.
6. Pachmann K, Camara O, Kavallaris A et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008;26:1208-1215.
7. Mïler V, Stahmann N, Riethdorf S et al. Circulating tumor cells in breast cancer: Correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005;11:3678-3685.
8. Goss P, Allan AL, Rodenhiser DI et al. New clinical and experimental approaches for studying tumor dormancy: Does tumor dormancy offer a therapeutic target? APMIS 2008;116:552-568.
9. Link MP. Adjuvant therapy in the treatment of osteosarcoma. Important Adv Oncol 1986:193-207.
10. Meyers PA, Heller G, Healey J et al. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
11. Souhami RL, Craft AW, Van der Eijken JW et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-917.
12. Bruland OS, Hoifodt H, Saeter G et al. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005;11:4666-4673.
13. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001;20:5747-5754.
14. Delattre O, Zucman J, Plougastel B et al. Gene fusion with an ETS DNAbinding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-165.
15. Sorensen PH, Lessnick SL, Lopez-Terrada D et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994;6:146-151.
16. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
17. Paulussen M, Craft AW, Lewis I et al. Results of the EICESS-92 Study: Two randomized trials of Ewing sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008;26:4385-4393.
18. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114.
19. Schleiermacher G, Peter M, Oberlin O et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 2003;21:85-91.
20. Evdokimova V, Tognon C, Ng T et al. Translational activation of Snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009;15:402-415.
21. Nguyen DX, Bos PD, Massagué J. Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-284.
22. Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-352.
23. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001;13:555-562.
24. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-626.
25. Gilmore AP. Anoikis. Cell Death Differ 2005;12(suppl 2):1473-1477.
26. Grossmann J, Walther K, Artinger M et al. Apoptotic signaling during initiation of detachment-induced apoptosis ("anoikis") of primary human intestinal epithelial cells. Cell Growth Differ 2001;12:147-155.
27. Boudreau N, Sympson CJ, Werb Z et al. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995;267:891-893.
28. Meredith JE Jr, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-961.
29. Yawata A, Adachi M, Okuda H et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene 1998;16:2681-2686.
30. van Nimwegen MJ, van de Water B. Focal adhesion kinase: A potential target in cancer therapy. Biochem Pharmacol 2007;73:597-609.
31. Shaw LM, Rabinovitz I, Wang HH et al. Activation of phosphoinositide 3-OH kinase by the α6β4 integrin promotes carcinoma invasion. Cell 1997;91:949-960.
32. Dufour G, Demers MJ, Gagné D et al. Human intestinal epithelial cell survival and anoikis. Differentiation state-distinct regulation and roles of protein kinase B/Akt isoforms. J Biol Chem 2004;279:44113-44122.
33. Douma S, Van Laar T, Zevenhoven J et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004;430:1034-1039.
34. Cheng H, Liu P, Wang ZC et al. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal 2009:2:ra35.
35. Windham TC, Parikh NU, Siwak DR et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002;21:7797-7807.
36. Wei L, Yang Y, Zhang X et al. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene 2004;23:9052-9061.
37. Attwell S, Roskelley C, Dedhar S. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 2000;19:3811-3815.
38. Collins NL, Reginato MJ, Paulus JK et al. G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol 2005;25:5282-5291.
39. Lagadec C, Meignan S, Adriaenssens E et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009;28:1960-1970.
40. Zong CS, Zeng L, Jiang Y et al. Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem 1998;273:28065-28072.
41. Cheng TL, Symons M, Jou TS. Regulation of anoikis by Cdc42 and Rac1. Exp Cell Res 2004;295:497-511.
42. Lawlor ER, Scheel C, Irving J et al. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene 2002;21:307-318.
43. Idogawa M, Adachi M, Minami T et al. Overexpression of BAD preferentially augments anoikis. Int J Cancer 2003;107:215-223.
44. Schmelzle T, Mailleux AA, Overholtzer M et al. Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci U S A 2007;104:3787-3792.
45. Woods NT, Yamaguchi H, Lee FY et al. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 2007;67:10744-10752.
46. Hofbauer S, Hamilton G, Theyer G et al. Insulin-like growth factor-Idependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. Eur J Cancer 1993;29A:241-245.
47. Scotlandi K, Benini S, Sarti M et al. Insulin-like growth factor I receptormediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res 1996;56:4570-4574.
48. Toretsky JA, Kalebic T, Blakesley V et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-30827.
49. Martin MJ, Melnyk N, Pollard M et al. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 2006;26:1754-1769.
50. Scotlandi K, Maini C, Manara MC et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 2002;9:296-307.
51. Valentinis B, Reiss K, Baserga R. Insulin-like growth factor-I-mediated survival from anoikis: Role of cell aggregation and focal adhesion kinase. J Cell Physiol 1998;176:648-657.
52. Kim SY, Wan X, Helman LJ. Targeting IGF-1R in the treatment of sarcomas: Past, present and future. Bull Cancer 2009;96:E52-E60.
53. Manara MC, Landuzzi L, Nanni P et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007;13:1322-1330.
54. Kang HG, Jenabi JM, Zhang J et al. E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res 2007;67:3094-3105.
55. Prickett TD, Agrawal NS, Wei X et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009;41:1127-1132.
56. Eckert JM, Byer SJ, Clodfelder-Miller BJ et al. Neuregulin-1 beta and neuregulin- 1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells. Glia 2009;57:1501-1520.
57. Shen X, Kramer RH. Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. Am J Pathol 2004;165:1315-1329.
58. Mueller S, Cadenas E, Schönthal AH. p21WAF1 regulates anchorageindependent growth of HCT116 colon carcinoma cells via E-cadherin expression. Cancer Res 2000;60:156-163.
59. Ong A, Maines-Bandiera SL, Roskelley CD et al. An ovarian adenocarcinoma line derived from SV40/E-cadherin-transfected normal human ovarian surface epithelium. Int J Cancer 2000;85:430-437.
60. Schafer ZT, Grassian AR, Song L et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009;461:109-113.
61. Fung C, Lock R, Gao S et al. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 2008;19:797-806.
62. Algrain M, Turunen O, Vaheri A et al. Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J Cell Biol 1993;120:129-139.
63. Khanna C, Wan X, Bose S et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-186.
64. Arpin M, Algrain M, Louvard D. Membrane-actin microfilament connections: An increasing diversity of players related to band 4.1. Curr Opin Cell Biol 1994;6:136-141.
65. Fazioli F, Wong WT, Ullrich SJ et al. The ezrin-like family of tyrosine kinase substrates: Receptor-specific pattern of tyrosine phosphorylation and relationship to malignant transformation. Oncogene 1993;8:1335-1345.
66. Wan X, Mendoza A, Khanna C et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65:2406-2411.
67. Wan X, Kim SY, Guenther LM et al. β4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene 2009;28:3401-3411.
68. Chiarugi P, Giannoni E. Anoikis: A necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008;76:1352-1364.
69. Janes SM, Watt FM. Switch from αvβ5 to αvβ6 integrin expression protects squamous cell carcinomas from anoikis. J Cell Biol 2004;166:419-431.
70. Marco RA, Díaz-Montero CM, Wygant JN et al. α4 integrin increases anoikis of human osteosarcoma cells. J Cell Biochem 2003;88:1038-1047.
71. Diaz-Montero CM, Wygant JN, McIntyre BW. PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer 2006;42:1491-1500.
72. Cantiani L, Manara MC, Zucchini C et al. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res 2007;67:7675-7685.
73. Rothberg KG, Heuser JE, Donzell WC et al. Caveolin, a protein component of caveolae membrane coats. Cell 1992;68:673-682.
74. Goetz JG, Lajoie P, Wiseman SM et al. Caveolin-1 in tumor progression: The good, the bad and the ugly. Cancer Metastasis Rev 2008;27:715-735.
75. Fiucci G, Ravid D, Reich R et al. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002;21:2365-2375.
76. Wiechen K, Sers C, Agoulnik A et al. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol 2001;158:833-839.
77. Bangma CH, Nasu Y, Ren C et al. Metastasis-related genes in prostate cancer. Semin Oncol 1999;26:422-427.
78. Ho CC, Huang PH, Huang HY et al. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002;161:1647-1656.
79. Tirado OM, Mateo-Lozano S, Villar J et al. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 2006;66:9937-9947.
80. Zhang H, Su L, Mïler S et al. Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. Br J Cancer 2008;99:1684-1694.
81. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-358.
82. Shor AC, Keschman EA, Lee FY et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007;67:2800-2808.
83. Hingorani P, Zhang W, Gorlick R et al. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 2009;15:3416-3422.
84. Bolós V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007;28:339-363.
85. Engin F, Yao Z, Yang T et al. Dimorphic effects of Notch signaling in bone homeostasis. Nat Med 2008;14:299-305.
86. Hilton MJ, Tu X, Wu X et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 2008;14:306-314.
87. Zhang P, Yang Y, Zweidler-McKay PA et al. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008;14:2962-2969.
88. Engin F, Bertin T, Ma O et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 2009;18:1464-1470.
89. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett 2008;272:177-185.